同和藥業(300636.SZ)通過高新技術企業認定
格隆匯 1 月 12日丨同和藥業(300636.SZ)公佈,公司於2007年被認定為高新技術企業,並取得相關部門頒發的《高新技術企業證書》,之後又通過數次複審及重新認定。2020年公司根據相關規定又進行了高新技術企業重新認定申報工作,並於近日收到江西省科學技術廳、江西省財政廳、國家税務總局江西省税務局聯合頒發的《高新技術企業證書》。
根據有關規定,公司通過高新技術企業認定後,將連續三年(即2020年、2021年、2022年)繼續享受關於高新技術企業的相關優惠政策,按15%的税率繳納企業所得税。鑑於公司2020年已根據相關規定暫按15%的税率計徵了企業所得税,因此,該事項不會對公司2020年已披露定期報吿中的經營業績產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.